News
06-03-2012, 11:23 PM
Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
More... (http://www.news-medical.net/news/20120604/Results-from-Pumae28099s-PB272-Phase-I-combination-trial-on-metastatic-HER-2-positive-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20120604/Results-from-Pumae28099s-PB272-Phase-I-combination-trial-on-metastatic-HER-2-positive-breast-cancer.aspx)